हिंदी में पढ़ें Zee Business हिंदी

Biocon

Biocon Biologics secures USFDA approval for cancer treatment biosimilar

Biocon Biologics secures USFDA approval for cancer treatment bios...

Thu, Apr 10, 2025

The company already markets the biosimilar under the brand name Abeymy in Europe and Canada.

Union Budget 2025: Healthcare sector gets Rs 98,311 crore; pharma stocks in focus

Union Budget 2025: Healthcare sector gets Rs 98,311 crore; pharma...

Sat, Feb 01, 2025

Budget 2025 boosts healthcare with Rs 98,311 crore allocation, expanding medical education and cancer care while easing drug costs. Pharma stocks gain momentum amid duty cuts and PLI incentives.

Storm intensifies in Biocon!

Storm intensifies in Biocon!

Tue, Jan 07, 2025

Why the sharp rise in Biocon? Biocon Biologics is preparing to launch many new biosimilars, know the full news

TRENDING NOW

Biocon, Zentiva get EU approval for generic diabetes, weight management drug

Biocon, Zentiva get EU approval for generic diabetes, weight mana...

Tue, Dec 24, 2024

The approval is for the generic versions of Victoza to treat Type-2 Diabetes and Saxenda used in the treatment of weight management

Should you buy, sell or hold L&T, Tata Power, Biocon, other stocks now?

Should you buy, sell or hold L&T, Tata Power, Biocon, other s...

Thu, Oct 31, 2024

Share Market News: Here's how brokerages view a bunch of stocks today, including Larsen & Toubro, Tata Power and Biocon.

Biocon gets 4 observations from USFDA for Bengaluru API facility

Biocon gets 4 observations from USFDA for Bengaluru API facility

Sat, Sep 28, 2024

The US Food and Drug Administration (USFDA) conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru from September 23- 27, 2024.

LIC raises stake in Biocon to 5.02%

LIC raises stake in Biocon to 5.02%

Wed, Sep 18, 2024

The company has increased its shareholding in equity shares of Biocon Ltd to 5.023 per cent.

Axis Direct picks JSW Steel, Balrampur Chini, Biocon and 2 other stocks for 15 days; check out targets and stop losses

Axis Direct picks JSW Steel, Balrampur Chini, Biocon and 2 other...

Mon, Sep 16, 2024

Axis Direct has given a 'buy' rating on Balrampur Chini. The brokerage has given a target of Rs 638 and a stop loss of Rs 560. This means the stock has an upside of 12 per cent from its last closing price.

Stock of The Day: Today Anil Singhvi gave the opinion of buying in Eicher Motor, ABB and selling in SAIL and BIOCON

Stock of The Day: Today Anil Singhvi gave the opinion of buying i...

Fri, Aug 09, 2024

Stock of The Day: Today Anil Singhvi gave the opinion of buying in Eicher Motor, ABB and selling in SAIL and BIOCON. What are stoploss and targets? See in this video.

Which stocks will be in focus today including Eicher Motors, ABB India, Biocon and SAIL?

Which stocks will be in focus today including Eicher Motors, ABB...

Fri, Aug 09, 2024

Which stocks will be in focus today including Eicher Motors, ABB India, Biocon and SAIL? On the basis of which news there will be action in the market? What are the important triggers for the market? Know here.

Biocon Biologics got approval from the European Medicines Agency to manufacture biosimilar Bevacizumab in India

Biocon Biologics got approval from the European Medicines Agency...

Mon, Jun 24, 2024

Biocon Biologics, a subsidiary of Biocon, on Monday got approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab in India.

Biocon gets 4 observations from USFDA for Andhra Pradesh facility

Biocon gets 4 observations from USFDA for Andhra Pradesh facility

Sat, Jun 22, 2024

The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024, the company said in a regulatory filing.

Biocon Q4 results: Net profit falls 57% to Rs 136 crore; revenue at Rs 3,966 crore

Biocon Q4 results: Net profit falls 57% to Rs 136 crore; revenue...

Thu, May 16, 2024

The company posted a net profit of Rs 313 crore in the January-March quarter of the last fiscal. Total revenue rose marginally to Rs 3,966 crore in the fourth quarter compared with Rs 3,929 crore in the year-ago period, Biocon said in a statement.

Biocon partners Biomm to commercialise diabetes drug in Brazil

Biocon partners Biomm to commercialise diabetes drug in Brazil

Wed, Apr 17, 2024

Biomm focuses on developing, manufacturing and commercialising complex biotech and biosimilar drug products at its production facility in Nova Lima.

Biocon shares jump as unit signs long-term deal with Eris Lifesciences

Biocon shares jump as unit signs long-term deal with Eris Lifesci...

Thu, Mar 14, 2024

Biocon shares extended their intraday gains in late afternoon deals on Thursday after the biopharmaceuticals firm said its subsidiary, Biocon Biologics, had entered into a long-term commercial coll

Unlocking Opportunities: Biocon, Aarti Industries, Zomato - What's the Right Move After Results?

Unlocking Opportunities: Biocon, Aarti Industries, Zomato - What...

Fri, Feb 09, 2024

Should you sell Biocon after the results? Aarti Industries' results are weak, but should you buy the stock? HOLD Zomato as investment after excellent results? Know the analysis on the results from Anil Singhvi...

Biocon shares slip over 4.5% after Q3 results, partnership with Sandoz

Biocon shares slip over 4.5% after Q3 results, partnership with S...

Fri, Feb 09, 2024

Biocon share price: The company on Thursday reported a consolidated net profit of Rs 660 crore for the third quarter ended December 31, 2023, on the back of robust sales. It reported a net loss of Rs 42 crore in the October-December period of the last fiscal.

Biocon Q3 results: Company posts net profit at Rs 660 crore

Biocon Q3 results: Company posts net profit at Rs 660 crore

Thu, Feb 08, 2024

"A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of USD 200 million towards the acquisition-related debt reduction," Biocon Executive Chairperson Kiran Mazumdar Shaw said.

Biocon Q3 preview: Firm likely to post profit of Rs 192 crore against a loss in Q3 FY23

Biocon Q3 preview: Firm likely to post profit of Rs 192 crore aga...

Thu, Feb 08, 2024

EBITDA, or earnings before interest, taxes, depreciation, and amortisation, is also set to log a double-digit increase of 29 per cent in Q3 to Rs 830 crore as against Rs 646 crore logged in Q3 FY23.

Biocon jumps after inking deal with Sandos for distribution of FKB injection in Japan

Biocon jumps after inking deal with Sandos for distribution of FK...

Tue, Dec 26, 2023

Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co. Ltd., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics Ltd affiliate.

Biocon's subsidiary completes integration of Viatris’ biosimilars business; stock rises

Biocon's subsidiary completes integration of Viatris’ biosim...

Fri, Dec 01, 2023

Biocon share price: At around 10:42 a.m., Biocon shares were up 1.51 per cent, or Rs 3.6, at Rs 242.05 apiece on BSE. The market capitalisation of the company stood at Rs 29,060.52 crore at around the same time.

Biocon Q2 nos miss estimates; brokerages cut targets; stock slips

Biocon Q2 nos miss estimates; brokerages cut targets; stock slips...

Mon, Nov 13, 2023

At around 9:50 a.m., shares of Biocon traded 3.85 per cent, or Rs 9.05 lower, at Rs 225.75 apiece. The market capitalisation of the company stood at Rs 27,169.58 crore.

Biocon Q2 Results Preview: Biocon likely to bank on Viatris acquisition; sales, margin may soar considerably

Biocon Q2 Results Preview: Biocon likely to bank on Viatris acqui...

Wed, Nov 08, 2023

Biocon Q2 Results Preview: Biocon's biologics sales are set to double, while margin can also improve considerably due to the integration of American pharma firm Viatris, as the Ben

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x